News and Comments


  Wednesday, April 28, 2010

Despite the emergence of new biological treatments for cancer, Chemotherapy is still essential, and indispensable as a major treatment for malignancies. The adverse events caused by these chemicals were found to be acceptable as a risk versus the great reward of using chemotherapy. The technological evolution that took place in the past decade and the surfacing of state-of-the-art technologies such as nanotechnology, scientists believed possibilities exist now for improving the adverse effect profiles of these therapeutic molecules. Reformulating the existing products has become an increasingly common product lifecycle-management technique. We read that a 2004 report on the U.S. drug market from BCC, Inc. projected that reformulations would grow from 62% of the market in 2003 to 79% in 2008. Finding ways to modify and improve existing products’ side effect profiles has become feasible after being essential but unreachable goal.  More...

Recent Postings



Sangamo (SGMO) RenenxBio (RGNX) Sarepta (SRPT) TOKAI (TKAOI) C4 Therapeutics Illumina (ILMN) ACADIA (ACAD) ImmunoGen (IMGN) Elan (ELN) Agenus (AGEN SUNESIS PHARMACEUTICALS (SNSS) Anadys (ANDS) ABBVIE (ABBV) NEKTAR (NKTR)) Bristol-Myers Squibb (BMY) Telaprevir Tysabri REGULUS (RGLS) Agenus (AGEN) Merck (MRK) SYNTA (SNTA) Micromet (MITI) KERYX (KERX) Intermune (ITMN) galapagos (GLPG) Herceptin Sanofi-Aventis (SAN) INNOVIVA (INVA) Prosensa (RNA) Alnylam (ALNY) Dendreon (DNDN) Aimmune Therapeutics (AIMT) Zerenex Velcade (bortezomib) Gilead (GILD) Exelixis (EXEL) Dynavax (DVAX) JUNO (JUNO) Inovio (INO) Ionis (IONS) Revlimid (lenolidamide) Ocular Therapeutix (OCUL) CRISPR Therapeutics (CRSP) Seattle Genetics (SGEN) Xoma (XOMA) NANTKWEST (NK) Editas (EDIT) Onyx (ONXX) AERIE PHARMACEUTICALS Human Longevity (HLI) ZALTRAP™ VANDA (VNDA) Anacor (ANAC) Incyte (INCY) Adaptimmune (ADAP) Mirati Therapeutics (MRTX) Ridaforolimus CompuGen (CGEN) NOVOCURE (NVCR) Ariad (ARIA) Galena (GALE) Array Pharmaceuticals (ARRY) Amgen (AMGN) Multiple Myeloma Auspex (ASPX) KITE (KITE) Ziofpharm (ZIOP) Sanofi (SNY) Benlysta (belimumab) Roche (RHHBY) BIOMARIN (BMRN) GlaxoSmithKline (GSK) ISIS (ISIS) Pluristem (PSTI) ARGOS (ARGS) Rapamune Valeant Pharmaceuticals International (VRX) Jazz Pharmaceuticals (JAZZ) Human Genome Sciences (HGSI) Vitae Pharmaceuticals (VTAE) ADVENTRIX (ANX) Regeneron (REGN) IDERA (IDRA) SERES THERAPEUTICS (MCRB) Alder Biopharmaceuticals (ALDR) Intercept (ICPT) Vertex (VRTX) Advaxis (ADXS) AGOS (ARGS) Roche (ROCHE) Bellicum (BLCM) CEMPRA (CEMP) Sequenom (SQNM) Abbott Laboratories (ABT) Theravance Bio Pharma (TBPH) HALOZYME (HALO) Endometrial Cancer Spike Therapeutics (ONCE) Sanofi (SNA) OSI (OSIP) PTC Therapeutics (PTCT) Trastuzumab-DM1 Idenix (IDIX) AstraZeneca (AZN) Intrexon (XON) Theravance (THRX) Prolor Biotech (PBTH) ARCA (ABIO) Global Cell Therapeutics (GBT) Biocryst (BCRX) Cytokinetics (CYTK) MODERNA GUARDIAN HEALTH Biogen Idec (BIIB) Genentech